Sundlöv, Anna
Gleisner, Katarina Sjögreen
Tennvall, Jan
Ljungberg, Michael
Warfvinge, Carl Fredrik
Holgersson, Kajsa
Hallqvist, Andreas
Bernhardt, Peter
Svensson, Johanna http://orcid.org/0000-0003-3292-7719
Funding for this research was provided by:
Fru Berta Kamprads Stiftelse (FBKS-2019-44-270, 2020-8-270, 2020-8-270)
Cancerfonden (CAN 2018/577, 2015/266, 2018/747)
Stiftelsen Konung Gustaf V:s Jubileumsfond (2020/309)
The ALF agreement (ALFGBG-723481)
University of Gothenburg
Article History
Received: 13 October 2021
Accepted: 28 March 2022
First Online: 22 April 2022
Declarations
:
: The trial was conducted in accordance with ICH GCP and the Declaration of Helsinki and was approved by the regional ethics review board (EPN Lund 2011/287).
: Informed consent was obtained from all participants in this trial.
: All authors agree with the submitted version of the manuscript. The material submitted for publication has not been previously reported and is not under consideration for publication elsewhere.
: Anna Sundlöv declares having received speaker honoraria from Novartis, Ipsen, and Sam Nordic, advisory board fees from Advanced Accelerator Applications, and consultancy fees from Spago Nanomedical.